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OBJECTIVES: The primary objective of the Diabcost
study was to determine the cost of type 2 diabetes in 
Australia. Additional objectives were to collect data on
quality of life, health service use and indirect costs for
people with type 2 diabetes, and to improve understand-
ing of the burden on carers. METHODS: A paper-based
questionnaire was used to collect cross-sectional survey
data. Approximately 25,000 questionnaires were mailed
to people on a national diabetes database and responses
were received from 10,652 people. Respondents were
asked to self-report three months’ retrospective data.
Questions covered demographic information, health
status (including history of microvascular and macrovas-
cular complications), health service utilisation, cost to
people with diabetes, lost productivity and quality of life
(EQ-5D). A separate questionnaire ﬁlled in by carers
covered carer burden. Derivation of costs used a combi-
nation of costs and charges. RESULTS: The mean annual
cost per individual with type 2 diabetes was $A7565.
There were direct costs of $A5325 (comprising $A4260
in health care and $A1065 in non health care costs). Self-
reported indirect costs were $A35 and carer costs were
$A2150. When the population was divided into four
groups based on history of complications, it was clear
that more complications resulted in higher average costs.
The cost for respondents with no complications was
$A4025, with microvascular complications only was
$A7025, with macrovascular complications only 
was $A9055 and with both complications was $A9645.
Utilities and quality of life also differed for the four
groups. The overall cost of type 2 diabetes in Australia
was calculated to be $A3 billion. CONCLUSIONS: Type
2 diabetes impacts signiﬁcantly on affected individuals
and their carers. Onset of macrovascular and microvas-
cular complications increases the burden of illness
through deterioration in quality of life and increased costs
to the community.
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OBJECTIVE: To develop a model to evaluate the cost-
effectiveness of starting patients with Diabetes Mellitus
on lifelong therapy with ACE-Is immediately on diagno-
sis. Although apparently already a dominant strategy for
renal protection in diabetes, ACE-Is are not prescribed to
patients immediately on diagnosis of Type II diabetes.
Determining whether they have overall cost-effectiveness
in preventing cardiac endpoints may be useful in updat-
ing treatment guidelines. METHODS: Interventions:
Treating patients with DM with ACE-Is immediately on
diagnosis vs. not using ACE-Is. Design: Age-speciﬁc life-
time costs and QALYs associated with each of the end-
points: MI, stroke and ESRD, were estimated for each
intervention strategy. Time Horizon: Lifetime. Perspec-
tive: Societal. Target Population: The model was esti-
mated in females aged 40 and over. Model measures:
discounted lifetime cost, discounted quality-adjusted 
life expectancy for each strategy. Incremental cost-
effectiveness ratio. Data Sources: Randomized control
trials estimating the effect of ACE-Is on the occurrence of
each endpoint, life tables for mortality and life expectancy
data, epidemiological and observational studies to esti-
mate the added risk for each endpoint contributed by dia-
betes, and quality of life/health utility studies to estimate
QALYs associated with each endpoint. RESULTS: Base-
Case Analysis: Immediately starting therapy with ACE-Is
was shown to be a dominant strategy. Starting from age
40, this strategy would save total discounted lifetime costs
of $63,835 and improve discounted quality-adjusted 
life expectancy by almost 2 years. Sensitivity Analysis:
Although still indicating a dominant strategy, both life-
time costs and QALYs are sensitive to the discount rate
used, and lifetime costs are highly sensitive to the lifetime
cost of ESRD management. CONCLUSIONS: Starting all
patients with Type II DM on lifelong ACE-I therapy is a
simple strategy that provides greater beneﬁt at a lower
cost. It may be worth considering its implementation as
a standard diabetes patient management strategy.
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OBJECTIVES: To simulate the cost-effectiveness of two
different treatment regimens for type 2 diabetes patients.
METHODS: Cost-effectiveness was measured as cost per
life years gained (LYG) and cost per quality adjusted life
years gained (QALY). A standard Monte Carlo simula-
tion combining published literature for risk of long-term
diabetic complications with risk functions for each com-
plication was used. Clinical outcomes were based upon
the following long-term diabetic complications: cardio-
vascular, neuropathy, nephropathy, and retinopathy. Life-
time costs were calculated as the yearly costs for drugs
plus cost for complications (US Medicare perspective)
over a 30-year period, and clinical outcomes and lifetime
costs were discounted at 3%. Patient baseline data were
taken from a randomized, multicenter trial, comparing a
treatment regimen of repaglinide plus metformin vs.
nateglinide plus metformin for type 2 diabetic patients.
After dose adjustments to achieve glycemic targets,
median ﬁnal daily doses were 5mg repaglinide and 
360mg nateglinide. RESULTS: The reduction in A1c
values from baseline was -1.28% point (p < 0.001) and
